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Blood, sweat, and tears: developing clinically
relevant protein biosensors for integrated body
fluid analysis
S. R. Corrie,*a,b,c J. W. Coffey,a,c J. Islam,a,c K. A. Markeyd,e and M. A. F. Kendalla,b,c,f
Biosensors are being developed to provide rapid, quantitative, diagnostic information to clinicians in order
to help guide patient treatment, without the need for centralised laboratory assays. The success of glucose
monitoring is a key example of where technology innovation has met a clinical need at multiple levels –
from the pathology laboratory all the way to the patient’s home. However, few other biosensor devices are
currently in routine use. Here we review the challenges and opportunities regarding the integration of bio-
sensor techniques into body fluid sampling approaches, with emphasis on the point-of-care setting.
Introduction
Biosensors aim to deliver important diagnostic data into the
hands of patients or their treating clinicians in real-time,
without the need for centralised laboratory infrastructure. Bio-
sensor technology can be applied in a variety of clinical set-
tings: (a) the emergency situation where urgent diagnostic
information will change the course of treatment, e.g. acute cor-
onary syndromes;1 (b) the hospital inpatient setting where
immediate results are more desirable even though full patho-
logy laboratory testing may be available, e.g. standard blood
panel;2 (c) the outpatient setting where a test result is required
to dictate overall management but this has not been attended
to by the patient ahead of time, e.g. quarterly HbA1 c monitor-
ing in diabetic patients,3 or (d) in the patient home for screen-
ing or follow-up, e.g. glucose monitoring.4 In addition to these
examples, biosensors can be used in low-resource settings
without the need for highly trained medical staff, and have the
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potential to greatly improve patient care5 in disease outbreaks
where complex sample handling is undesirable (e.g. the recent
West African Ebola epidemic6,7). The endocrinology commu-
nity has been at the forefront of the clinical adoption of bio-
sensor technology with patient-driven glucose monitoring
becoming a mainstay of diabetes care since the 1970’s.4
Indeed, this trend has continued with the widespread adop-
tion of in-office testing of HbA1c (a measure of aggregate gly-
caemic control over the preceding 3 months),3,8 however
relatively few assays/methods move beyond the central
laboratory.
A biosensor is comprised of three key operations – first the
sample collection, followed by assay chemistry, and finally,
detection and recording of a quantifiable signal (noting that
the chemistry/transduction are often linked). The combined
assay/detection technique that has proven most successful in
making the transition from the central lab to the point-of-care
involves detection of small molecules, e.g. glucose, lactate,
using enzymatic electrochemical methods. Detecting larger
molecules, e.g. proteins, lipids, nucleic acids, etc., is a much
more challenging problem, mainly due to non-specific adsorp-
tion of body fluid components at transducing sensor surfaces,
and the general lack of enzyme/analyte pairs for many protein
targets. However progress is being made in the development of
affinity-based sensors to meet this need, and is reviewed else-
where.9 However, progress at the sampling stage lags behind
both the assay chemistry and detection methods in terms of
research output and perceived importance.10,11 Accordingly,
the majority of sample collection and processing techniques,
for any class of analyte, are still reliant on 20th, and in some
cases, 19th century technology (e.g. needles and blood tubes12).
It is thus becoming clear that significant research effort needs
to be directed to the development of innovative body fluid
sampling strategies that integrate or simplify the downstream
operations of the diagnostic testing process.
Looking to the future, it is likely that lower abundance ana-
lytes will be of increasing importance to meet the goals of
early disease detection, and biosensors should be key tools in
this emerging field. Instead of non-specific metabolites and
electrolytes (e.g. the standard blood panel which includes
glucose), these are more likely to be disease-specific proteins,
nucleic acids, lipids, or even whole cells, which have been vali-
dated in discovery-focused studies.13–15 In recent times, a
range of ultra-sensitive bioassays has been developed to par-
tially address this challenge, often incorporating aspects of
nanoparticles and nanotechnology, and mainly using affinity-
based interactions between analytes and antibodies, aptamers,
ionophores, or other high-affinity binders, all of which have
been thoroughly reviewed elsewhere.2,16–19 However, given that
the blood volume of a human is on the order of 5 L, and the
interstitial fluid volume is ∼17 L,20 the relatively low abun-
dance of these biomarkers leads to an inexorable statistical
sampling issue which cannot be solved without addressing the
limitations of bulk fluid sampling. As elegantly described
by Labuz et al.10 and Mariella et al.11 Poisson statistics
dictates that as analyte concentration is reduced, the prob-
ability increases that a collected sample of body fluid does not
contain any analyte (37% from 1 mL of sample containing a
concentration of 1000 molecules per L). Unchecked,
this would (or possibly already has, in some circumstances)
lead to a stochastic distribution of false negative results,
which have nothing to do with the downstream assays chem-
istry or detector sensitivity – it is simply that the sample
volume may not contain the analyte. This could certainly
be the case in the emerging areas of ultra-sensitive
protein detection (<fg mL−1),21 circulating tumor cells (<50
cells per mL),10 and microbial sepsis (<100 cfu mL−1).22
In these cases, it is likely that novel sampling approaches
will be required in combination with ultra-sensitive detection
tools.
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The ultimate application of a clinical biosensor is to
measure the concentration of a biomarker (or panel thereof),
in a real-time, continuous manner directly in body fluids. This
would reduce the need for frequent sample collection and
potentially open up new approaches in biomarker-guided
therapeutic intervention.23 It is also considered the ultimate
goal because if biosensors were capable of real-time sample
monitoring, it follows that they could also be applied to simple
endpoint testing applications. Some would argue that biosen-
sors, by their very nature, are already capable of real time and
continuous sensing (e.g. real time binding kinetics, etc.).
However, as the majority of applications involve measurement of
an analyte in an isolated sample, this definition does not apply
to the practice of monitoring analyte concentrations in real time.
The benefits of real-time monitoring must be connected with
real time sampling to meet this ultimate clinical utility.
The purpose of this review is to identify emerging protein
biosensor technologies applied in clinically relevant situations
using integrated body fluid sampling strategies. We have
deliberately used a broad definition of the term “biosensor” so
as to capture emerging technologies. However, we limit our
scope generally to bioanalytical methods that currently or
potentially combine all three steps of a diagnostic process into
an integrated device, requiring minimal sample processing or
user input (e.g. washing steps), and for which a quantifiable
indicator of analyte concentration can be detected,
preferably in real time. A focus on in vitro bioassays is there-
fore beyond the scope of this review, and readers are directed
to a range of other excellent reviews on related topics through-
out this review.
Technical complexities of diagnostic sampling
Body fluids are highly complex mixtures that contain a variable
concentration of cells, proteins, macromolecules, metabolites
and small molecules. Complex biochemical reactions occur
naturally in these fluids (e.g. blood clotting), hence it is logical
that removal and handling of these fluids by either passive
(e.g. urine collection) or active (e.g. the standard blood draw)
methods can alter the composition, resulting in problems
prior to the assay even being performed. This issue is com-
monly referred to as “pre-analytical variability,” and even with
recent improvements in quality control and standardization in
clinical laboratories, it is estimated that over 90% of errors in
the diagnostic process are related to this problem.24 There is
already evidence that this problem affects the performance of
biosensors exposed to body fluids, even those diluted or other-
wise treated to account somewhat for the variation.10 Taking
blood as a case in point, many studies have identified changes
in biomarker levels as a function of time to analysis,25,26
different collection tubes and associated fittings,12,25 and the
degree of hemolysis (ruptured red cells leak hemaglobin into
serum/plasma which changes colour of the sample leading to
inaccurate results in optical assays12), which is in turn affected
by the sampling method, sampling site, needle gauge, collec-
tion flow rate and the size/flow properties of the specific vein
involved. Clearly, attempts to address the issue of pre-analyti-
cal variability at the sampling stage could pass “savings” on
downstream.
Clinical complexities of diagnostic sampling
There are significant practical aspects of sample collection
that are rarely discussed in the context of analytical device
development. In the clinical setting, poor venous access is a
key limitation in the delivery of intravenous therapies, but it
can also be problematic for simple sample collection in some
patients. Access to a vein for routine blood sampling relies on
a trained health care professional to visually identify a reason-
able vein, then perform accurate venepuncture and maintain
sterility both during and in-between sampling events and tube
changes. Factors contributing to difficulty in accessing veins
for peripheral cannulation and sample collection include:
extremes of patient weight, clinician inexperience, and clini-
cian judgement of poor venous access.27–29 Other contributors
include: extremes of patient age, exposure to cytotoxic drugs
(e.g. previous chemotherapy), anatomical factors (e.g. previous
surgical procedures close to sampling site), and prolonged
hospital stay requiring the siting of multiple short-term peri-
pheral cannulae. Collection of other fluids can also be highly
reliant on clinician skill (e.g. lumbar puncture to collect cere-
brospinal fluid which also requires patient sedation), and
patient’s ability to produce a sample in accordance with instruc-
tion (e.g. urine). Uncontaminated urine can also be difficult to
collect in unwell patients or the elderly, confused, incontinent
of urine, or who require permanent indwelling catheters. Cir-
cumventing these complex and user-dependent collection
methods with biosensors could therefore improve access to
diagnostic information for significant number of patients.
Comparing different body fluids
Table 1 compares and contrasts key aspects of the body fluids
under review. Sample collection methods vary widely across
the fluids. They are dominated by bulk fluid sampling
approaches that pass complex samples into the downstream
assay/detection processes, potentially limiting sensitivity and
specificity due to contamination of sensing surfaces with non-
specific material. Some methods are more acceptable to some
patients (e.g. urine preferred to blood; but either would be pre-
ferable to lumbar puncture); some methods could be classified
as “active” or “passive” (i.e. either requiring the patient to
actively produce the sample versus passive collection). While
most fluids have a physiological pH range similar to that of
blood, it is interesting to note that both urine and sweat are
quite acidic, and also have quite a variable pH range, which
would certainly be expected to affect biosensor readings.
While there is significant variation in total protein concen-
tration across the fluids, with blood or plasma the most con-
centrated fluids, others including saliva, tears, and skin fluid
contain a relatively high concentration as well. Encouragingly,
all of the fluids possess both a unique proteome (20–40% in
comparison with blood plasma) highlighting the need for
body fluid-specific assays; yet there is enough overlap with
blood in many cases to highlight that there may be situations
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in which blood sampling is not required to access circulating
analytes. It is important to note that the analysis may not be
that simple; indeed the data presented in Table 1 does not
take into account key complexities in the molecular weight dis-
tribution of proteins in each fluid, nor the relative concen-
tration of individual proteins, which can cover 12 orders of
magnitude for blood alone.20,61 Finally, body fluids all appear
to show non-Newtonian, shear-thinning, behaviour as a func-
tion of shear rate. Interestingly, some fluids (saliva, blood,
plasma) show this behaviour more than others, which could
be considered to have constant visco-elastic properties under
most testing conditions (e.g. urine, sweat, CSF). However, to
our knowledge this is an incomplete dataset as the visco-
elastic behaviour of these fluids have not all been investigated,
thoroughly or otherwise.
Biosensor application with commonly
sampled fluids
Blood is the most commonly collected sample for clinical diag-
nostics, and the blood proteome and the range of clinical tests
available are thoroughly reviewed elsewhere.20,61 As most cell
and tissue excretory products present in the blood, it contains
a mixture of classic plasma proteins, secreted proteins, short-
and long-range receptor ligands, tissue leakage products, aber-
rant secretions and foreign proteins, along with metabolites
and electrolytes – many of which can be correlated to disease
diagnosis, progression ad treatment response. Over 200 pro-
teins are used in clinically approved tests in the USA61 and the
standard blood panel of metabolites and electrolytes (sodium,
potassium, chloride, calcium, bicarbonate, glucose, urea and
creatinine) is the lab test most frequently requested by clini-
cians.7 Lateral flow assays have proven extremely successful in
providing a simple and minimally invasive biosensor options
for consumers (e.g. pregnancy testing), and especially in
remote locations (e.g. infectious diseases) and have been
thoroughly reviewed recently by Yetisen et al.62 However they
are directly reliant on lancets or needles for sample collection,
and are unlikely to find application in real-time applications.
Electrochemical analysis is also commonly employed here and
is well-suited to the detection of low-molecular weight mole-
cules, and is also the basis of most implantable devices, as
described thoroughly by Bernhardt et al.63 (fundamental
basis) and Kotanen et al.64 (applications) in recent reviews.
However, this approach requires both (a) an analyte-specific
enzyme which reacts with the analyte to produce a detectable
current at a transducing surface, and (b) a low molecular
weight cut-off filter surrounding the device that reduces non-
specific interference by allowing only the passage of low mole-
cular weight species to the sensor. However, if the device is to
be operated in vivo, or if large macromolecules or proteins are
the target analytes, then non-specific adsorption of blood pro-
teins interferes significantly with the electrochemical signal. To
overcome this limitation, new strategies are being developed for
affinity-based electrochemical sensors.9 Optical approaches are
also being developed, for which non-specific adsorption does
not necessarily affect the optical detection signal.
In one of the very few examples of an electrochemical assay
using an affinity-based approach for real-time sensing, Fergu-
son et al.65 recently demonstrated real-time detection of doxor-
ubicin, a chemotherapy agent, in a real-time, continuous assay
in rats in vivo (Fig. 1A). The “MEDIC” device comprises a cath-
eter inserted into the patient that diverts blood (∼0.75 mL h−1)
into a microfluidic device containing an electrochemical,
aptamer-based sensor. Upon specific drug binding, the
aptamer probe undergoes a reversible conformational change
that modulates electron transfer between the terminally bound
methylene blue redox reporter and the electrode. Importantly,
the aptamer also showed rapid kinetics (kon ∼ 3 µM−1 min−1
Table 1 Key properties of human body fluids
Body fluid Sampling techniques pH
Unique proteins
(%, in comparison
to plasma)
Total protein concentration
(mg mL−1)
Viscosity
(mPa s)
Blood Needle, lancet 7.35–7.4530 NA 60–80 mg mL−1 30 Serum: 1.52–1.5431
Plasma: 1.58–1.6031
1.18–1.2832
Blood: 4.69–5.2 (92 s−1)31
4.25–4.61 (583 s−1)31
Saliva Swab 6.2–7.433 38,34 3135 0.2–5 mg mL−1 36 2–8 (90 s−1)37
1.5–4 (90 s−1)38
Urine Passive collection
or catheter
4.5–8.039 3040 <150 mg per day excreted39
and <0.1 mg mL−1 41
0.6–1.242
CSF Lumbar puncture 7.31–7.3543 40,44 2845 1 : 20–1 : 10046 (blood plasma) 0.55–0.7 (360–1460 s−1)47
0.7–0.74 (5–100 s−1)48
Tear fluid Swab, contact lens 6.5–7.549 3450 6–10 mg mL−1 50,51 1.5–3 (20–160 s−1)52
Exhaled
breath
Bag, cold trap 7.5–7.6553 — 1–4 mg mL−54 —
Sweat Swab, tattoo 4.0–6.855 2056 0.1–0.7 mg mL−1 57 0.9197
Interstitial
fluid (skin)
Tape-strip, iontophoresis,
microdialysis,
microneedle array
7.2–7.458 3259 13–20 mg mL−1 60 —
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and koff ∼ 1.35 µM−1 min−1) such that the doxorubicin concen-
tration in the blood could be monitored stably over ∼4 hours.
A crucial aspect of the design is the inclusion of a “continu-
ous-flow diffusion filter”, in which a buffer stream flowing
across the sensor is combined with the blood flow, in a
laminar regime, such that only the molecules with large
enough diffusion constants (e.g. small molecule drugs) are
able to diffuse from the blood into the buffer in sufficient time
to be detected by the sensor. This filter serves the same
purpose as the polymeric matrices employed in traditional
electrochemical devices, with the same limitation that develop-
ing assays for larger protein analytes could be problematic.
Using a custom-designed algorithm based on the charge-trans-
fer kinetics to reduce sensor drift, the MEDIC device is
capable of stable, continuous, quantitative monitoring of dox-
orubicin in human blood for at least 4 hours.
An interesting alternative to the routine blood panel analy-
sis has been developed in Clark’s group (reviewed here3), invol-
ving the in vivo analysis of analyte-specific fluorescence in a
real-time and continuous format (Fig. 1B). These “optodes”
(named based on their conceptual similarity to ion-selective
electrodes) consist of plasticised microparticles that are loaded
with analyte-specific ionophores and a pH-sensitive fluo-
rescent dye. In the absence of analyte, the ionophore is proto-
nated, but upon selective binding of the analyte, the dye
deprotonates to maintain the charge balance in the particle,
resulting in a concentration-dependent change in optical pro-
perties. This approach has been used to measure common
blood panel analytes, both in vitro66 but also in a real time,
continuous manner. Clark’s group have demonstrated that fol-
lowing injection of the particles into the subcutaneous tissue,
various small molecules and electrolytes (including hista-
mine,67 sodium,68 glucose69) can be measured in real-time by
whole body fluorescence imaging, and most recently via
photo-accoustic imaging.70 This approach is extremely promis-
ing, however again a key challenge is to move beyond the stan-
dard blood panel for real-time, continuous monitoring of
proteins and other macromolecules. Furthermore, optical
detection methods that are practical in clinical environments
are yet to emerge.
Saliva has a long history of use in clinical diagnostics due
to the ease of sample collection (swab or passive drool) and
the wide variety of both host biomarkers and those associated
with infection. A key issue with saliva, as shown in Table 1, is
the extreme range of fluid viscosity, which is a key challenge
for device engineering. While there has been significant
Fig. 1 Examples of emerging biosensor technologies for commonly sampled body fluids. (A) “MEDIC” device, which incorporates a microfluidic
chamber fed with blood via a catheter (i), detecting doxorubicin in a reversible and real-time manner, using an aptamer-based affinity electrochemi-
cal assay, using a “continuous-flow diffusion filter” to limit non-specific fouling of the electrode (iii); (B) optode microparticles that, upon injection in
to the subcutaneous tissue of mice (i), can be used to measure the levels of small molecule electrolytes/metabolites in a continuous manner (ii); (C)
electrochemical enzymatic sensor (ii) integrated into a mouthguard (i) for continuous monitoring of lactate in saliva. Images for (A–D) adapted with
permission from references 65, 67, 75 and 97, respectively.
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overlap with blood serum observed in terms of proteomics, the
concentration of protein in saliva is significantly lower (∼30%)
and there are additional dynamic changes relating to diet and
fluid intake.36 Nasopharyngeal fluid is a related sample that
can also be collected from the nasal passages for specific
pathogen detection, and is currently routinely collected for res-
piratory virus DNA via PCR, often for a multiplex panel of 6–8
common viruses.71 There is often a lengthy waiting period
between sample collection and the attainment of final results,
an issue that has been problematic during influenza epi-
demics (e.g. H1N1).72,73 Development of sensitive protein bio-
sensors may help to rapidly identify the disease-causing
pathogen in a timely fashion in some cases. Biosensors have
been applied to detect a range of analytes including small
molecules (lactate,74,75 cortisol,76,77 biogenic amines78), pro-
teins and organisms (salivary alpha-amylase,79–84 CA15-3,85
influenza virus,86 mutans streptococci87,88). These studies
generally used optical immunoassay approaches to detect
those proteins for which no enzyme partner was apparent, or
enzymatic electrochemical assays (in the case of amylase).
Interestingly, Aluoch et al.84 developed an electrochemical
immunoassay biosensor for salivary amylase which compared
favourably to a sensitive ELISA, however it has not yet been
tested in real fluids. However, in nearly all of these cases,
saliva was collected via the “passive drool” method and often
processed (e.g. by dilution, buffer exchange, etc.) prior to analy-
sis, hence limiting the potential for real-time sample analysis.
A mouthguard sampling device recently developed by Kim
et al.74 is a novel collection device with the potential to convert
the current trend of passive, end-point saliva sampling into a
minimally-invasive continuous monitoring system (Fig. 1C).74
Since salivary lactate concentrations correspond well to blood
lactate levels, the former is of interest in fitness monitoring.
The mouthguard consists of a polyethylene terephthalate
(PET) substrate coated with a printable Prussian-Blue (PB)
transducer, and overlaid with lactate-oxidase enzyme
entrapped in poly-orthophenylenediamine (PPD). The PB
transducer detects the hydrogen peroxide products of the
oxidase reaction, while the PPD acts to protect the biosensor
surface and prevent fouling. In buffered media, the sensor
could detect lactate in saliva over the physiological range, with
a detection limit of ∼0.1 mM. Addition of physiological levels
of other electroactive species (ascorbic acid and uric acid) had
negligible effect on the lactate detection at 0.5 mM, suggesting
the PPD layer provided adequate protection. In human saliva
samples, the device measured background lactate levels at
∼0.01 mM, which is in the normal range for unstimulated
saliva, with a linear response to 0.5 mM. In continuous oper-
ation mode, the device was tested every 10 minutes over a
2 hour period, without significant loss of function. Future
work will focus on miniaturization of circuits, and detailed
toxicology and biocompatibility analysis.
Urine is a commonly collected sample for clinical and non-
clinical testing, especially due to the ease of collection, usually
without the need for invasive procedures. Invasive sampling is
occasionally required in infants where a suprapubic aspirate is
performed for collection of a sterile sample, or the incontinent
elderly where an ‘in-out’ catheter must be inserted and then
withdrawn from the urinary bladder. Lateral flow assays have
also been designed for endpoint analysis of a range of analytes
including pregnancy hormones, glucose, bilirubin, ketones
and drugs of abuse.62 Indeed, these devices are far better
suited to urine than blood, because the latter requires lancets
or needles to provide the sample to be analysed. However,
urine samples require active production of the sample by the
patient, which can then only be used for endpoint analysis.
Furthermore, as demonstrated in Table 1, only analyte amount
can be quantified for urine analysis, as the volume produced
by different people at different times renders concentration
readings effectively meaningless. Urine biosensors applied to
human sampling have typically focussed on enzymatic small
molecule analysis, that may be indicative of renal tract patho-
logy (oxalate,89 glucose,90–92 uric acid93–95), with more complex
systems emerging to detect proteins. In one case the authors
reported detection of bladder cancer marker NMP2296 in clini-
cal samples using an electrochemical affinity-based biosensor,
although samples needed to be diluted 1 : 10 in buffer for suc-
cessful quantitative detection. Samples are usually collected in
a suitable vessel for endpoint analysis, followed by processing
via buffer dilution and/or pH neutralization, and solids
removal. However, for continuous analyte detection, the best
example is the development of smart catheter devices that
respond to the presence of infectious agents.
Integration of biosensors into in-dwelling urinary catheters
can be used to provide early warning of infection. The key
advantage of such systems is that a real-time and continuous
indication can be provided, without relying on active partici-
pation by the patient, which can identify signs of infection
days before catheter lines become encrusted and blocked.
While these devices might not be considered to fit the tra-
ditional definition of a biosensor, their clinical application is
aligned. For example, Stickler et al. have developed a sensor
which can be placed inside a catheter bag which changes
colour in response to pH changes. The pH change is usually
related to the presence of pathogens in the urine, and could be
used as an early indicator of line infection prior to catheter
blockage (Fig. 1D). The sensor consisted of a pH-sensitive dye
(Bromothymol Blue – BTB) embedded in a cellulose acetate
matrix. Infections caused by P. mirabilis and other urease-posi-
tive microorganisms causes increase in pH of urine, and the
sensor changes colour ∼12 hours following infection, in a
model system.97 This compared to ∼55 h for blockage of cath-
eter due to encrustation, which is usually the clinical endpoint
reached prior to replacement which may require emergency
referral. The sensor was then tested in a clinical trial to assess
performance in comparison to blockage time.98 The sensor
only changed colour in response to P. mirabilis infection
(15 patients), and did not change colour in samples from
patients where the infection was not identified (5 patients).
Importantly, in agreement with the earlier study, the sensor
was able to detect infection up to 12 days prior to catheter
blocking, so that catheter replacement could be performed
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long before emergency referrals were necessary. Recently an
improved design was reported that overcame previous manu-
facturing limitations that prevented scale-up. The new material
was based on a PDMS substrate, and the sensing reagents
could be incorporated into the 2-part curing system.99 The
newer device showed similar performance to the original in
clinical trials,100 and further work is planned to further reduce
the time between sensor colour change and catheter blockage,
to reduce the number of replacements required for any
given patient.
Cerebro-spinal fluid is an excellent example of an important
clinical sample that must be collected to rule out potentially
life-threatening conditions, for which there is no viable biosen-
sor. Sampling is painful for patients, and currently requires
the presence of highly practiced medical professionals,
whereby a needle is inserted into the space between L3 and L5
lumbar vertebrae to withdraw fluid. CSF is a clear, colourless
fluid which in health, has a lower cell count and significantly
lower protein concentration than blood (Table 1). The most
common reason to sample this fluid is to establish the pres-
ence of central nervous system (CNS) pathology (e.g. infection,
malignancy, autoimmune disease), and is also sometimes
used in the acute setting to rule out meningitis. Recent studies
have also shown detection of amyloid-products in the CSF of
patients with dementia and related conditions,101 and given
that at least 20% of the CSF proteome is unique when com-
pared to blood (Table 1), more CSF-specific biosensors are
likely to emerge if convenient sampling approached are develo-
ped. To date, no viable alternative to LP-sampling has been
developed (outside the setting where the patient has an extra
ventricular drain inserted, often for continuous monitoring of
CSF pressures and removal of excess fluid as a therapeutic
approach). Hence new non-invasive (or less-invasive) tech-
niques for body fluid analysis of CSF and cranial fluids could,
at the very least, reduce the pain and discomfort for patients,
but could also facilitate the development of novel tests for
CNS-related diseases. While this field is in its infancy, readers
are directed to a recent ACS virtual issue (“Chemistry and the
BRAIN initiative) that highlights recent progress and future
directions.102
Exhaled breath is of particular interest in the analysis of
breath volatile organic compounds (VOCs),103,104 which can be
related to a range of respiratory conditions (e.g. asthma,
smoking-related illnesses, cystic fibrosis, etc.) and other dis-
eases. A key example is fractional exhaled nitric oxide (FENO)
which is significantly increased in the breath of asthma
patients and others with lung inflammation.105 Protein-con-
taining material can also be isolated using a cold-trap system
to condense the gas103 however analysis of the breath conden-
sate is technically challenging.106 To date, the predominant
protein species in this fluid are type I and II cytokeratins (orig-
inating from the lung), along with inflammatory cyto-
kines.107,108 Traditionally, analysis of exhaled breath is carried
out using gas chromatography and mass spectrometry, both of
which currently are limited to centralised laboratories. In
recent years, there has been more interest in the use of biosen-
sors, which could potentially offer a quick and inexpensive way
for detection of breath analytes. End-tidal carbon dioxide
monitoring is used routinely in hospitals (both in intensive
care units and in surgery) to measure the carbon dioxide con-
centration in the breath of intubated patients,109 using a
simple optical approach. A number of studies describe the
development of electrochemical arrays for single or multi-
plexed analyte detection (“electronic noses”),104,110–115 yet as
there are no widely accepted standardised methodology for
sample collection and analysis,116 development and use of
breath testing for the purpose of disease diagnostic has been
limiting.103 The availability of simple devices for collection of
exhaled breath and condensate (e.g. the RTube™ – a nebulizer
that non-invasively captures expired breath condensate under
normal breathing) may speed up device development, and
several groups appear to be integrating sensors into these
devices.117,118
Biosensor application with emerging
body fluids
Analysis of tear fluid is a relatively new concept, and to date
glucose is the only analyte targeted for detection. The concen-
tration of glucose in tears has been shown to be highly corre-
lated to blood glucose with a lag time of ∼10 minutes making
tear glucose sensors a worthwhile alternative to finger pricking
for repetitive or continuous monitoring. Tears are also a prom-
ising fluid for protein detection, given the appreciable protein
concentration and unique protein content (Table 1). However,
to date no published studies are available on biosensing in
this context. One of the challenges when sampling tear fluid
for a quantitative readout, is that any irritation can cause an
increase in tear production leading to a reduction in bio-
marker concentration.119 There are several potential solutions
which have been explored such as minimally invasive capillary
collection at the corner of the eye120 to calibration with a con-
tinuous monitoring device such as an electrode embedded
contact lens.121 Many groups have turned to contact lenses
(Fig. 2A) because a significant amount of research has already
been carried out on the fabrication, biocompatibility and
fouling mechanisms on these surfaces,122 as discussed in a
recent review.123 The substrates chosen for biosensor construc-
tion (excluding electrodes) are almost exclusively polymeric in
nature due to the biocompatibility and fouling properties that
can be produced. Although some early work was performed on
disposable fluorophore-doped contact lenses,124,125 electroche-
mical detection has since become the favoured method of
quantification,120,126,127 due to the ease of integration with
continuous and wireless readouts.121,128 The optimisation of
enzyme and electrodes for glucose detection in tear fluids is
an active area of research.129
Sweat is an acidic, electrolyte-rich fluid whose production is
induced by exercise and results in secretion of metabolites
including lactate, glucose and uric acid.55 However, in terms of
biosensor systems in development, efforts have focussed on
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the electrochemical detection of the metabolites lactate,
glucose and uric acid, because the protein content is extremely
low (Table 1). Sample collection methods include simple swab-
bing of the skin, or fluid collection with a microsyringe,
however these methods are yet to be integrated with sensors.
The Macroduct™ system uses iontophoresis in the presence of
pilocarpine to induce and then collect sweat fluid, which has
been used for clinical sodium chloride analysis for cystic fibro-
sis diagnostics, and also in proteomic studies of sweat.56,130
Sample collection tools that can be applied for continuous
analysis, or those that do not rely on active sweat production
could result in very useful biosensors, due to the non-invasive
nature of analysis. However the key limitation is that patients
cannot easily control their sweat production for sampling/ana-
lysis, and it is also affected significantly by environmental
factors including temperature and humidity.
An example of a continuous sweat “tattoo” biosensor was
developed by Jia et al.131 for measurement of exercise-induced
lactate (Fig. 2B). The device consists of a screen-printed elec-
trode on a flexible substrate, with lactate oxidase immobilised
onto the working electrode with multi-walled carbon nano-
tubes acting as the transducer surface, and tetrathiafulvalene
(TTF) added to enhance low-voltage electrocatalytic conversion
of lactate. Testing carried out in vitro, with the sensor attached
to both rigid and flexible substrates, showed that the ampero-
metric response was stable to repeated mechanical bending,
was unaffected by the presence of physiological concentrations
of other metabolites (e.g. creatinine, ascorbic acid, glucose,
uric acid), and had a linear response rate for lactate of
1–20 mM (typical physiological levels up to 25 mM). Epidermal
testing was also performed over ∼30 minute period of exercise,
with excellent agreement to laboratory testing. Colorimetric
analysis of sweat pH and metal ions has also been demon-
strated in sweat in situ by Huang, et al.132 Such devices could
be extremely useful in a range of non-invasive applications,
especially if advances are made that facilitate sensitive protein
detection (as discussed with regards to blood). However, this
method is limited in that sufficient electrolyte fluid (sweat)
must be in contact with the sensor for the amperometric signal
generation; hence it currently relies on active sweating.
While the composition and origin of skin interstitial fluid
(ISF) remain difficult to define,133 its diagnostic potential
arises from its ease of access, high degree of vascularisation,134
and passage of blood biomarkers into the ISF under hydro-
Fig. 2 Examples of emerging biosensor technologies for emerging body fluids. (A) A contact lens glucose sensor showing the sensor construction
(i) and real-size comparison (ii). (B) Sweat tattoo sensor (i) designed for enzymatic electrochemical lactate detection (ii), with the sensor shows
applied to skin (iii), and the real-time readout on an exercising human (iv). (C) Schematic of emerging skin sampling devices, based on iontophoresis
(i), microdialysis (left) and ultrafiltration (right) (ii), and microneedle array (iii). Images (A) and (B) adapted with permission from ref. 123 and 131,
respectively.
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static and osmotic pressure. In particular, skin capillary
vessels readily exchange fluid and small molecules with the
ISF, whilst having a lower permeability towards macromole-
cules, such as proteins.135 Thus, much of the focus on skin
sampling to date has been on using ISF as a proxy for blood
sampling of small molecules, such as glucose,136,137 lactate,138
cortisol,139 and urea.140 While analysis of the skin ISF pro-
teome for biosensing applications has been largely overlooked,
several studies suggests that macromolecular biomarkers orig-
inating from blood may also be readily accessed from the ISF,
along with unique skin-specific proteins.59,141 The lack of
interest in protein-based skin biosensors to date has been
partly due to the challenges associated with developing affinity
based biosensors (as discussed for other fluids), and partly
due to a lack of convenient approaches developed to sample
skin fluid. A number of local skin diseases such as, eczema,
psoriasis, cancer and skin based infections present opportu-
nities for diagnosis by altering skin chemistry (pH) and other
biomarkers, as recently covered in a review by Paliwal et al.142
Furthermore, the skin’s role in preferentially accumulating
some disease markers originating from other sites was also
noted, such as amyloid B from Alzheimer’s disease and bio-
markers of cardiovascular disease risk. A range of bulk fluid/
tissue sampling approaches have thus been developed, which
include tape stripping, suction blisters and biopsies. Others
including iontophoresis, microdialysis and microneedles have
been integrated with biosensors and tested in pre/clinical
models. One issue that has received little attention is the
damage caused to the skin using these approaches, which may
in turn affect the levels of target analytes.
In reverse iontophoresis (RI) an electrical current is applied
to the skin surface to extract charged, and by inducing fluid
flow, uncharged molecules for subsequent analyte detection
(Fig. 2C(i)). RI has been demonstrated for the sampling of a
range of small analytes including phenylalanine143,144 urea140
and glucose.136,145 The best known example of an RI extraction
system with an incorporated biosensor (in this case electroche-
mical) is the GlucoWatch Biographer.136 This device was
approved in humans and was commercially available for
continuous glucose measurement, providing reasonable pre-
diction of blood glucose levels. The device, however, was even-
tually withdrawn due to a high false positive rate.146 Although
RI is not biomarker selective, molecules migrate to different
extents according to their charge and size, which can provide
selective purification of the sample during extraction.147 This
typically limits the extraction of proteins, which has the
benefit of reducing fouling to electrochemical sensors, and in
the case of glucose measurement, results in migration of
common electroactive interfering molecules to the non-
sensing electrode compartment. Recently, the Wang group has
developed a proof of concept wearable “tattoo” device that
incorporates an RI system with electrochemical glucose detec-
tion,148 using a low-potential Prussian-Blue transducer that
potentially allows for more selective and sensitive analysis. Fol-
lowing successful in vitro characterization of the specific elec-
trochemical response of the sensor to glucose, the device was
trialled on human volunteers by detecting an increase in
glucose levels following a meal.
Microdialysis (MD) employs a semi-permeable probe
inserted into the dermis or subcutaneous tissue, enabling par-
tially selective sampling of proteins and small molecules
based on the membrane molecular weight cutoff (MWCO) of
the probe (Fig. 2C(ii)).149–151 The implanted MD probe is per-
fused with an isotonic liquid that collects molecules below the
MWCO of the membrane through diffusion, which can then
be collected and analysed. Since the pioneering work of
Jansson et al.149 and Anderson et al.150 in the late 1980’s MD
has been extensively used for the measurement of small
molecules,152–154 whilst some high molecular weight mole-
cules have also been detected, including cytokines (IL-6 ∼
29 kDa),154 albumin,155 and high molecular weight dextrans
(in vitro only, up to 150 kDa).156 Sampling of large molecules is
somewhat limited, however, due to the loss perfusate from
probes with very large effective pores, reducing sample recov-
ery.155 Capillary ultrafiltration is a related technique, which
can sample larger proteins by using a vacuum to withdraw ISF
through a MWCO probe, hence not requiring perfusate. To
date the application of MD has been primarily limited to scen-
arios where its invasiveness is far outweighed by benefit of
early detection of complications arising during surgery and
intensive care.153,157 MD has, however, been demonstrated for
continuous glucose measurement in self-monitoring glucose
devices,158–160 such as the GlucoDay,158 with good correlation
to blood glucose levels. While well suited to continuous moni-
toring and generally excluding fouling proteins from electro-
chemical sensors,161 MD inherently involves a significant lag
time due to the slow pumping rates required allow equili-
bration of analyte155 and probes are prone to long term
fouling and degradation.162,163
Microneedles (MNs) and MN arrays consist of hollow pro-
jections typically hundreds of microns to a few millimetres
long, with an inner channel diameter less than 100 µm
(Fig. 2C(iii)).164,165 These MNs/MN arrays penetrate through
the outer epidermal layers of the skin to provide direct access
to ISF and blood with reduced invasiveness, making them suit-
able for repeated or real time monitoring. Without the mole-
cular weight cutoff issues of MD probes, MNs/MN arrays offer
the potential for real time sampling of small and large mole-
cules at the ISF concentration. In principle this includes phar-
macokinetics, metabolites (glucose, lactate, glutamate),138,166
ions (Na+, K+ and pH),138,167 cytokines, proteins (infectious
disease, cardiovascular disease) and RNA/DNA. Furthermore,
microfabrication technology used for MN fabrication is com-
patible with miniaturised fluid handling and electrochemical
sensor fabrication meaning MNs can easily be integrated with
backside compartments for processing and analyte recog-
nition/transduction. In pioneering work, Zimmermann
et al.168 demonstrated the first MN array for ISF glucose
measurement consisting of 8 × 8 hollow MNs integrated with a
flow through sensor which extracted ISF by capillary force and
was shown to detect glucose in human skin in vivo. The chan-
nels, however, did not continue to passively extract ISF once
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filled at a sufficient rate for real time glucose measurement,
suggesting more complex systems with active extraction (such
as pumps) may be required for continuous monitoring. A
similar concept was demonstrated by Mukerjee et al. in
human skin,169 however, glucose was detected qualitatively
with a glucose test strip, rather than with a sensor. In a series
of publications the Narayan and Wang groups have developed
hollow MN arrays integrated with solid carbon fibre, carbon
paste or Pt electrodes within the MN channels themselves.
Using these MN array electrodes they have employed electro-
chemical detection schemes for hydrogen peroxide,170
lactate,138,170 glucose and glutamate166 detection in vitro with
the ultimate aim of developing a wearable sensor. Significantly
they have also demonstrated multiplexed detection of pH,
glucose and lactate in vitro using a single MN array.138 To date,
however, this promising approach has not been demonstrated
in vivo in human skin.
In our own group, solid MNs arrays (i.e. microprojection
arrays or MPAs) have been also been developed to sample
protein biomarkers from the skin, including IgG,171,172 dengue
NS1 protein173 and malaria pfHRP2.174 To our knowledge this
is the first demonstration of MNs or MPAs to sample skin pro-
teins either selectively or non-selectively. The surface of these
MPAs were modified with biorecognition probes that selec-
tively capture circulating proteins from skin ISF/blood, which
has been demonstrated to be highly selective for the target
protein. Thus, the collected sample represents only a mole-
cular fraction and avoids fluid handling and processing. A
wearable version of this design has also been demonstrated to
increase the total amount of protein captured in vivo for up to
6 h,171 which may have application to accumulate low concen-
tration or rare analytes over extended periods that are not
otherwise detectable in small fluid volumes.175 Although this
approach achieves selective sampling of proteins from ISF/
blood, at this early stage analyte is detected with in vitro assays
upon MPA removal from skin and is not integrated with a bio-
sensor, though future designs aim to incorporate this with an
external biosensor cartridge.
Emerging trends and future
opportunities
There are some interesting trends identified in this review, par-
ticularly when it comes to the challenge of detecting proteins
and other macromolecules in body fluids in vivo or, without
significant sample processing, in vitro. We suggest that con-
sideration of the issues and concepts in the following discus-
sion could open up new research areas and possibly lead to
innovative solutions to key challenges in this field.
The concept of “selective sampling” approaches is emerg-
ing to avoid the processing of bulk samples, of which the
majority is irrelevant to the outcome of the test. This approach
is not necessarily all that new, as it is the basis of how glucose
monitoring and related electrochemical devices are able to
operate in complex fluids, namely via encapsulation of the
device in a polymeric matrix to limit mass transport of large
molecules to the sensor. However, new methods are emerging;
the most promising of which may be the direct enrichment of
a target analyte at a surface whilst in contact with a body fluid
in vivo, or at least without treating an extracted sample. In our
group, we have used this approach to develop microneedle sur-
faces with anti-fouling polymers and affinity probes, in order
to selectively extract protein analytes from the skin ISF. Several
of the methods highlighted here use a similar approach –
Clark’s group directly inject their nanosensors thus avoiding
sampling; Ferguson’s study effectively “diverted” a small but
continuously flowing blood sample into an analyte-selective
microfluidic channel; and Wang’s group have moved the
sensor directly into the body fluid (saliva, sweat, or skin) for
selective monitoring of small molecules. Indeed, the utility of
the selective sampling approach across a wide variety of body
fluids and biosensor platforms suggests that it could be
applied across a range of methodologies, regardless of the
detection techniques employed.
While the examples raised in this review are predominantly
in vivo examples, there is no reason why selective sampling
approaches could not also be integrated with emerging in vitro
diagnostic devices. An excellent example is the case of micro-
fluidics technologies, for which a significant device footprint
is required for bulk sample processing prior to biomarker iso-
lation and detection.10,11 The rapid expansion of microfluidic
technologies has opened up a plethora of new opportunities in
diagnostics,176,177 however bulk sampling with needle or
lancet devices remains the predominant sample collection
approach. Integration of microfluidic approaches with selec-
tive body fluid sampling could not only remove the need for
sample processing operations on these devices, but could also
help to address the challenge of rare event analysis. In the case
of circulating tumor cell analysis, there is already a significant
number of microfluidic devices available to isolate these cells
from blood samples;178,179 if they could be used to isolate
these very rare cells from the entire blood volume of a patient,
in a minimally invasive manner, this could significantly
improve the clinical utility of these devices. Ferguson’s study
shows that microfluidic systems can indeed be integrated into
body fluid sampling for real-time and continuous monitoring
approaches, and we hope to see more demonstrations of this
in the future, for a range of different classes of biomarkers.
We suggest that a number of relatively commonly collected,
or easily collected, body fluids have been under-utilised in
clinical biosensor development. Each fluid has its own list of
technical and clinical challenges in terms of utility, this broad-
ening range of fluids sampled may provide clinicians with
more diagnostic options. While blood, saliva, urine, and to a
lesser degree subcutaneous tissue (mainly for implantable
glucose sensors) have been widely used, the prospect of using
relatively protein-rich fluid, with unique proteome sub-sets, is
certainly intriguing. Furthermore, the comparison between
body fluids that are related by physiology (e.g. blood, skin ISF,
subcutaneous tissue, sweat) could also yield new insights into
biosensor development and disease investigations.
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Finally, the real-time and/or continuous approach is also
becoming popular. A common definition of a biosensor
includes the real-time/continuous attribute. However, end-
point analysis, is usually the goal for in vitro clinical sample
analysis, for which real-time and continuous measurements
have are usually not relevant, unless dynamic information (e.g.
activity/affinity or related measurements) is specifically
required. As biosensors become better integrated with body
fluid sampling, we expect that real-time analysis will open up
avenues into biomarker-directed therapies, with dynamic
information collected over time, from many parts of the body.
Certainly, we look forward to a future in which biosensor-
based approaches may indeed begin to tackle the immense
challenges in detecting low abundance analytes in complex
fluids in real-time, including ultra-low protein analytes, circu-
lating tumor cells, and microbial sepsis.
Conclusions
In conclusion, there is significant potential for the integration
of biosensors into clinical practice. However, in order to
achieve their full potential, we suggest that better integration
between body fluid sampling and the biosensor itself is
required. A key technical hurdle across all body fluids is the
jump from using enzymatic methods tailored to small mole-
cule analysis, through to approaches in which macromolecular
proteins and other analytes can also be detected in real-time,
with high specificity and selectivity. Furthermore, there are sig-
nificant opportunities for technology developers to develop
new methods to non-invasively analyse body fluids for which
there are currently very few acceptable approaches available, if
any.
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